#blcsm
LightNews LightNews
onclive.bsky.social
🎧 On this episode of #OncologyUnplugged, Chandler Park, MD, MSc, FACP, and @pgrivasmdphd.bsky.social, discuss bladder cancer data from #ESMO2026. @fredhutch.org @myesmo.bsky.social #blcsm #oncology

Watch on our site or listen on your favorite podcast platforms ➡️: www.onclive.com/view/periope...
October 31, 2026 at 1:34 AM
onclive.bsky.social
Ad hoc data from KEYNOTE-905/EV-303 showed consistent efficacy contributions for both enfortumab vedotin and pembrolizumab in cisplatin-ineligible MIBC #blcsm #oncology

Read more from #ESMO26: www.onclive.com/view/ad-hoc-...
October 23, 2026 at 9:13 PM
onclive.bsky.social
The addition of perioperative nivolumab to neoadjuvant chemo did not yield a statistically significant improvement in pCR rate or EFS vs neoadjuvant chemo alone in muscle-invasive bladder cancer #blcsm #oncology

Dive into the #ESMO26 data here: www.onclive.com/view/periope...
October 23, 2026 at 6:49 PM
onclive.bsky.social
Exploratory data from KEYNOTE-B15 showed enfortumab vedotin/pembrolizumab improved ctDNA clearance in cisplatin-eligible MIBC #blcsm #oncology

Check out the findings presented at #ESMO26: www.onclive.com/view/keynote...
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves ctDNA Clearance in Cisplatin-Eligible MIBC | OncLive
An exploratory analysis of the phase 3 KEYNOTE-B15 trial found that ctDNA status was strongly prognostic for event-free survival regardless of treatment arm.
www.onclive.com
October 24, 2026 at 1:00 AM
onclive.bsky.social
Perioperative pembrolizumab plus neoadjuvant chemo did not improve EFS vs placebo plus chemo in pts w/ cisplatin-eligible MIBC undergoing radical cystectomy with pelvic lymph node dissection, according to KEYNOTE-866. @myesmo.bsky.social #ESMO2026 #blcsm #oncology

www.onclive.com/view/pembrol...
Pembrolizumab Plus Chemo Misses EFS End Point in Cisplatin-Eligible MIBC | OncLive
The KEYNOTE-866 trial did not meet its EFS primary end point with perioperative pembrolizumab added to neoadjuvant cisplatin and gemcitabine.
www.onclive.com
October 23, 2026 at 11:16 PM
onclive.bsky.social
The EC has approved perioperative enfortumab vedotin plus pembrolizumab for the treatment of resectable MIBC, irrespective of cisplatin eligibility #blcsm #oncology www.onclive.com/view/pembrol...
Pembrolizumab Plus Enfortumab Vedotin Earns EC Approval in Resectable MIBC | OncLive
The European Commission approved pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, irrespective of cisplatin eligibility.
www.onclive.com
October 21, 2026 at 8:20 PM
onclive.bsky.social
🔍Just in: The @fda.gov accepted a new drug application seeking the approval of UGN-103 for recurrent low-grade intermediate-risk non–muscle-invasive bladder #blcsm #oncology

Read more on the target action date for approval and the UTOPIA data supporting the NDA: www.onclive.com/view/fda-acc...
FDA Accepts NDA for UGN-103 in Recurrent Low-Grade Intermediate-Risk NMIBC | OncLive
The FDA accepted an NDA for UGN-103 for recurrent low-grade intermediate-risk NMIBC, with a target action date of June 14, 2027.
www.onclive.com
October 19, 2026 at 4:13 PM
onclive.bsky.social
Did you miss this week's key updates in GEP-NETs, NMIBC, pancreatic cancer, and HCC? Test your knowledge with OncLive's weekly news quiz #blcsm #HCC #pancsm #oncology

www.onclive.com/view/onclive...
OncLive Weekly News Quiz (10/16/2026): Did You Miss Crucial Bladder, Neuroendocrine, Pancreatic, and Liver Cancer Updates? | OncLive
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
www.onclive.com
October 16, 2026 at 2:57 PM
onclive.bsky.social
📝 @fda.gov approvals in ccRCC and CCA, orphan drug and fast track designations in sarcoma, and a priority review in bladder cancer?

Test your knowledge with this week's news quiz: onclive.com/view/onclive...

#oncology #blcsm #kcsm #scmsm
OncLive Weekly News Quiz (9/26/2026): Did You Catch the Latest RCC, CCA, Sarcoma, and Bladder Cancer News? | OncLive
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
onclive.com
September 26, 2026 at 2:04 PM
onclive.bsky.social
Initial results from the phase 2 SURF302 trial showed the oral FGFR3-selective inhibitor dabogratinib generated responses in patients with FGFR3-altered low-grade, intermediate-risk NMIBC #blcsm #oncology

Read more: www.onclive.com/view/dabogra...
September 9, 2026 at 2:23 PM
onclive.bsky.social
Did you catch this week's top oncology news? Test your knowledge on updates in lung, bladder, and endometrial cancers #lcsm #gynsm #blcsm #oncology www.onclive.com/view/onclive...
OncLive Weekly News Quiz (8/21/2026): Did You Miss Key Lung, Bladder, and Endometrial Cancer Updates? | OncLive
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
www.onclive.com
August 21, 2026 at 1:23 PM
dytcmd.bsky.social
@ascocancer.bsky.social #GU26 the key findings:
#blcsm
K-M curves of ctDNA result K-M curves of ctDNA as dynamic biomarker ctDNA predicts extravesical not local disease Summary of conclusions
February 27, 2026 at 10:07 PM
dytcmd.bsky.social
@ascocancer.bsky.social A major late breaking abstract from Fox Chase: ctDNA informing outcome and prognosis for MIBC post-NAT and is a key parameter for risk-adapted management
An amazing presentation by Dr. Ghatalia, worth reviewing the recording again
#blcsm
Dr. Ghatalia giving talk of LBA at general session The protocol schema for ph2 single-arm RETAIN-2 trial
February 27, 2026 at 10:04 PM
dytcmd.bsky.social
#GU26 @ascocancer.bsky.social
Keynote-B15 results—significantly improves RFS/OS compared to Gem/Cis
#blcsm
Recurrence following EV/P v Cis/Gem OS results for EV/P v Cis/Gem
February 27, 2026 at 5:19 PM
dytcmd.bsky.social
#GU26 @ascocancer.bsky.social
Starting off with practice changing presentation of Keynote-B15:

Galsky reporting the unprecedented response surpassing Cis-Platin for NeoAdjuvant Treatment, this will cement EV/P as SOC for all MIBC
#blcsm
Galsky at the podium at GU ASCO Day 2 Keynote-B15 Protocol schema Protocol pathway and results
February 27, 2026 at 5:13 PM
dytcmd.bsky.social
#SUO24 #MarkTyson with great overview of expanding options in NMIBC #bladdercancer
Where we started…Where we are going #blcsm
Adjuvant bladder cancer treatments past to present Upcoming drug development for same space
December 5, 2024 at 6:07 PM
dytcmd.bsky.social
Q&A—how to apply ctDNA in medical management—differing approaches by the panel reflects lack of existing data on whether ready for prime time and if it shld lead to a change in care compared to using clinical/path alone. #blcsm #SUO24
dytcmd.bsky.social David Y.T. Chen @dytcmd.bsky.social · Dec 4
Day 1 #SUO24
Starting the afternoon discussing #bladdercancer therapy for adjuvant and in advanced disease.
➡️How far we’ve come beyond having largely just cystectomy. #blcsm
SUO24 1 pm Panel: J Wright, J Hoffman-Censits, O Mian, F Ghali Title slide for F Ghali’s talk
December 4, 2024 at 8:27 PM
dytcmd.bsky.social
Day 1 #SUO24
Starting the afternoon discussing #bladdercancer therapy for adjuvant and in advanced disease.
➡️How far we’ve come beyond having largely just cystectomy. #blcsm
SUO24 1 pm Panel: J Wright, J Hoffman-Censits, O Mian, F Ghali Title slide for F Ghali’s talk
December 4, 2024 at 8:03 PM
mtmdphd.bsky.social
Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines [May 20, 2022] Yap et al. @JAMANetworkOpen jamanetwork.com/journals/jam... #PrecisionMedicine #geneticcounselors #blcsm #lcsm
March 2, 2025 at 10:45 PM
mtmdphd.bsky.social
Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines [May 20, 2022] Yap et al. @JAMANetworkOpen jamanetwork.com/journals/jam... #PrecisionMedicine #geneticcounselors #blcsm #lcsm @TempusAI
Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines
This cross-sectional study examines the prevalence of germline findings in patients undergoing tumor/normal matched sequencing among cancer types lacking guidelines.
jamanetwork.com
January 30, 2025 at 2:54 PM
oncologynurseadv.bsky.social
In #NMIBC, immediate administration of 2 doses of neoadjuvant intravesical mitomycin C chemotherapy prior to TURBT may reduce recurrence and progression risks compared with TURBT alone. From @renalurologynews.bsky.social.

https://bit.ly/41gINY2

#blcsm #bladdercancer
Neoadjuvant Mitomycin C Before TURBT May Cut NMIBC Recurrence, Progression Risks - Oncology Nurse Advisor
A phase 2 trial evaluated the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in patients with urothelial non-muscle invasive bladder cancer.
bit.ly
March 22, 2026 at 7:19 PM
oncologynurseadv.bsky.social
Combined neoadjuvant treatment with ipilimumab and nivolumab followed by CRT shows promise as a bladder-sparing treatment for muscle-invasive #bladdercancer. From @natmed.nature.com and @renalurologynews.bsky.social.

Read more: ➡️ https://bit.ly/3MZPjiH

#MIBC #blcsm #UroOnc
Ipilimumab and Nivolumab With CRT May Be a Bladder-Sparing Treatment in MIBC - Oncology Nurse Advisor
The phase 2, single-arm INDIBLADE trial assessed induction ipilimumab plus nivolumab followed by CRT in patients with MIBC.
bit.ly
March 15, 2026 at 7:23 PM
oncologynurseadv.bsky.social
#BCG may be less effective in patients who develop metachronous #NMIBC after radical nephrouretectomy for #UTUC. Reported at #SUO25 by Yu Guang Tan, MBBS, of Singapore General Hospital covered by @renalurologynews.bsky.social.
https://bit.ly/4sJXtf5

#bladdercancer #blcsm
January 14, 2026 at 5:47 PM
oncologynurseadv.bsky.social
In patients with high-risk #MIBC, the 2-year locoregional failure-free survival rate was 87.1% with radiotherapy and 76.0% with observation. From @cancertherapyadv.bsky.social.

https://bit.ly/499ZqtR

#blcsm #bladdercancer
Adjuvant Radiotherapy Improves Locoregional Recurrence in High-Risk MIBC - Oncology Nurse Advisor
In patients with locally advanced muscle-invasive bladder cancer who have undergone radical cystectomy and chemotherapy, adjuvant radiotherapy improves survival outcomes compared to observation only.
bit.ly
November 14, 2025 at 9:13 PM
mskdeptofmed.bsky.social
A team of @mskcancercenter.bsky.social researchers led a study in mice evaluating KMT2C/D–KDM6A gene loss in #urothelialcarcinoma. While the loss of these genes promotes cancer, they may also make cells more sensitive to certain drugs. #blcsm @naturegenet.bsky.social www.nature.com/articles/s41...
Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A–menin to bivalent promoters - Nature Genetics
Loss of Kmt2c or Kmt2d in mice drives the redeployment of KMT2A–menin to bivalent promoters, leading to changes in gene expression. This primes cells for transformation and elicits sensitivity to EGFR...
www.nature.com
March 3, 2025 at 5:58 PM